Therapeutic targeting of the Jak/STAT pathway.

摘要: Antibodies that block cytokine function provide a powerful therapeutic tool especially for the treatment of autoimmune diseases. Cytokines are group small hydrophilic glycoproteins bind their receptors on cell surface and subsequently activate intracellular signalling cascades, such as JAK/STAT pathway. A bulk evidence has demonstrated genetic mutations in molecules can cause immunodeficiencies malignant growth. As result, several drug companies have begun to develop therapeutics inhibit JAK tyrosine kinases. Currently, two inhibitors, tofacitinib ruxolitinib, used clinic treating rheumatoid arthritis myeloproliferative diseases, respectively. Inhibiting been shown efficiently prevent uncontrolled growth cancerous cells harness overly active immune cells. In future, other molecule compounds likely come into clinical use, intense work is ongoing inhibitors specifically target constitutively mutant JAKs. This MiniReview will summarize basic features pathway, its role human disease potential inhibitors.